ArriVent BioPharma Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
AVBP$14.16+3.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| | Nine Months Ended | |||||
| · · September 30, | ||||||
| · 2024 · 2023 | ||||||
| Cash flows from operating activities: · · | ||||||
| Net loss | | $(59,855) | | $(48,140) | ||
| Adjustment to reconcile net loss to net cash used in operating activities: | | | | |||
| Stock-based compensation expense | | 2,256 | | 576 | ||
| Changes in operating assets and liabilities: | | | ||||
| Prepaid expenses and other current assets | | 36 | | 5,630 | ||
| Other assets | | (19) | | — | ||
| Accounts payable | | | 114 | | | 1,084 |
| Accrued expenses | | 3,406 | | (79) | ||
| Operating lease liabilities | | 2 | | — | ||
| Net cash used in operating activities | | (54,060) | | (40,929) | ||
| Cash flows from investing activities: | | | ||||
| Purchase of short-term investments | | — | | (25,000) | ||
| Net cash used in investing activities | | — | | (25,000) | ||
| Cash flows from financing activities: | | | ||||
| Proceeds from issuance of common stock in an initial public offering, net of issuance costs | | 185,950 | | — | ||
| Proceeds from the exercise of stock options | | 576 | | 69 | ||
| Proceeds from the sale of Series B convertible preferred stock, net of issuance costs | | — | | 44,919 | ||
| Payment of deferred offering costs | | — | | (1,072) | ||
| Net cash provided by financing activities | | 186,526 | | 43,916 | ||
| | | | | | | |
| Net increase (decrease) in cash and cash equivalents | | 132,466 | | (22,013) | ||
| Cash and cash equivalents at beginning of the period | | 150,389 | | 163,372 | ||
| Cash and cash equivalents at end of the period | | $282,855 | | $141,359 | ||
| | | | | | | |
| Supplemental disclosures of non-cash financing and investing activities | | | ||||
| Deferred offering costs in accounts payable | | $— | | $820 | ||
| Deferred offering costs transferred to additional paid in capital | | | 2,733 | | | — |
| | | | | | | |
| | | | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.